Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma

Annals of Hematology

Volumn 84, Issue 1, 2005, Pages 19-24

  Samani, Khalil Kargar ^a   Brazier, Michel ^b   Mathiot, Claire ^c   Kamel, Saïd ^b   Jamart, Jacques ^d   Jaubert, Jerome ^e   Blanc, Michel ^f   Azaïs, Isabelle ^g   Facon, Thierry ^h   Leleu, Xavier ^h  

^a Centre Hospitalier Mouscron   (Belgium)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c INSTITUT CURIE   (France)

^d UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^f Service de Medecine Nucleaire   (France)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AMINO TERMINAL TELOPEPTIDE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; DEXAMETHASONE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; PYRIDINIUM DERIVATIVE; PYRIDINOLINE;

AGED; ARTICLE; BONE DISEASE; BONE METABOLISM; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; URINALYSIS;

AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIDINIUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 10244252871     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0937-9     Document Type: Article

References (30)

1. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L (1997) Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol 96:103-110 10.1046/j.1365-2141.1997.8672495.x, 1:CAS:528:DyaK2sXhtVektLw%3D, 9012695
2. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L (2003) Comparison of five biochemical markers of bone resorption in multiple myeloma: Elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 120:235-242 10.1046/j.1365-2141.2003.04050.x, 1:CAS:528:DC%2BD3sXhs12ltrk%3D, 12542480
3. Alexandrakis MG, Passam FH, Malliaraki N, Katachanakis C, Kyriakou DS, Margioris AN (2002) Evaluation of bone disease in multiple myeloma: A correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 325:51-57 10.1016/S0009-8981(02)00246-2, 1:CAS:528:DC%2BD38XnsVShsb0%3D, 12367766
4. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733-737 1:STN:280:By2A2crmtV0%3D, 1638024
5. Bataille R, Chappard D, Basle MF (1996) Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies. Blood 87:4762-4769 1:CAS:528:DyaK28Xjt1Cks70%3D, 8639847
6. Blumsohn A, Naylor KE, Assiri AM, Eastell R (1995) Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 41:1592-1598 1:CAS:528:DyaK2MXpt1Onu7w%3D, 7586548
7. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT (2003) Serum test for assessment of patients with Bence Jones myeloma. Lancet 361:489-491 10.1016/S0140-6736(03)12457-9, 12583950
8. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S (1999) Evaluation of bone disease in multiple myeloma: A comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 62:300-306 1:STN:280:DyaK1M3osFGmsA%3D%3D, 10359057
9. Clark AD, Shetty A, Soutar R (1999) Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 13:79-90 10.1016/S0268-960X(99)90014-0, 1:STN:280:DyaK1MzktF2isg%3D%3D, 10414944
10. Colwell A, Eastell R (1996) The renal clearance of free and conjugated pyridinium cross-links of collagen. J Bone Miner Res 11:1976-1980 1:CAS:528:DyaK2sXjtVCksg%3D%3D, 8970901
11. Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, Passamonti F, Klersy C, Pascutto C, Canevari-Sciorati A, Lazzarino M (2001) Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 86:394-398 1:CAS:528:DC%2BD3MXks1ait78%3D, 11325645
12. Croucher PI, Apperley JF (1998) Bone disease in multiple myeloma. Br J Haematol 103:902-910 10.1046/j.1365-2141.1998.01082.x, 1:STN:280:DyaK1M7gtFeqsg%3D%3D, 9886299
13. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854 1:STN:280:CSmD2c7kvFI%3D, 1182674
14. Elomaa I, Virkkunen P, Risteli L, Risteli J (1992) Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66:337-341 1:STN:280:By2A28fosF0%3D, 1503907
15. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY (2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97:1566-1571 10.1182/blood.V97.6.1566, 1:CAS:528:DC%2BD3MXitFaltrk%3D, 11238092
16. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR (2000) Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 109:24-29 10.1046/j.1365-2141.2000.01960.x, 1:CAS:528:DC%2BD3cXksF2ksLo%3D, 10848778
17. Fontana A, Delmas PD (2000) Markers of bone turnover in bone metastases. Cancer 88:2952-2960
18. Fujimoto D, Suzuki M, Uchiyama A, Miyamoto S, Inoue T (1983) Analysis of pyridinoline, a cross-linking compound of collagen fibers, in human urine. J Biochem (Tokyo) 94:1133-1136 1:CAS:528:DyaL3sXlsFKgtLY%3D
19. Houze P, Bellik B, Brouet JC, Bouro F, Bousquet B (2000) Comparison of urinary markers for bone resorption in multiple myeloma. Clin Chim Acta 300:181-193 10.1016/S0009-8981(00)00323-5, 1:CAS:528:DC%2BD3cXlvV2nt7g%3D, 10958874
20. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 121:749-757
21. Jakob C, Zavrski I, Heider U, Brux B, Eucker J, Langelotz C, Sinha P, Possinger K, Sezer O (2002) Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 69:37-42 10.1034/j.1600-0609.2002.00505.x, 1:CAS:528:DC%2BD38XotlGhtrw%3D, 12270060
22. Jakob C, Zavrski I, Heider U, Bollow M, Schulz CO, Fleissner C, Eucker J, Michael R, Hamm B, Possinger K, Sezer O (2003) Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 9:3047-3051 1:CAS:528:DC%2BD3sXmtF2hs70%3D, 12912955
23. Kamel S, Brazier M, Desmet G, Picard C, Mennecier I, Sebert J (1992) High-performance liquid chromatographic determination of 3-hydroxypyridinium derivatives as new markers of bone resorption. J Chromatogr 574:255-260 10.1016/0378-4347(92)80037-Q, 1:CAS:528:DyaK38Xkt1alsrc%3D, 1618957
24. Kamel S, Brazier M, Rogez JC, Vincent O, Maamer M, Desmet G, Sebert JL (1996) Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency. J Clin Endocrinol Metab 81:3717-3721 10.1210/jc.81.10.3717, 1:CAS:528:DyaK28XmtlCmurY%3D, 8855828
25. Kamel S, Fardellone P, Meddah B, Lorget-Gondelmann F, Sebert JL, Brazier M (1998) Response of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake. Clin Chem 44:1437-1442 1:CAS:528:DyaK1cXktl2qurc%3D, 9665421
26. Nawawi H, Samson D, Apperley J, Girgis S (1996) Biochemical bone markers in patients with multiple myeloma. Clin Chim Acta 253:61-77 10.1016/0009-8981(96)06334-6, 1:CAS:528:DyaK28XlvVSlur0%3D, 8879839
27. Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Kohn H, Bayer P, Thiebaud D, Ludwig H (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridinium cross-links of collagen. Blood 90:3743-3750 1:CAS:528:DyaK2sXntVWjtb0%3D, 9345061
28. Seibel MJ, Woitge HW (1999) Basic principles and clinical applications of biochemical markers of bone metabolism: Biochemical and technical aspects. J Clin Densitom 2:299-321 10.1385/JCD:2:3:299, 1:STN:280:DC%2BD3c%2FhvVCrsA%3D%3D, 10548826
29. Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, Srivastava AK, Warnick GR, Watts NB, Myers GL (2002) Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin Chem 48:220-235 1:CAS:528:DC%2BD38XhtVyiu78%3D, 11805003
30. Withold W, Arning M, Schwarz M, Wolf HH, Schneider W (1998) Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation. Clin Chim Acta 269:21-30 10.1016/S0009-8981(97)00181-2, 1:CAS:528:DyaK1cXhtVOkurY%3D, 9498101